Products

Calcium-binding proteins (CaBPs) represent a novel therapeutic class for the treatment of the diseases of aging. Quincy Bioscience's intellectual property position allows us the opportunity to address these diseases with a known naturally occurring protein. With several conditions all possibly benefiting from the same therapeutic compound there exists several market opportunities from the same platform technology.

Unmet Clinical Need

An estimated 37 million people worldwide suffer from dementia, with Alzheimer's disease causing the majority of cases. Approximately 4.5 million Americans have Alzheimer's. Parkinson's disease, another central nervous system (CNS) disorder, affects more than 1.5 million people in the United States.